Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4556 Gene Editing

Trading 05-21 10:51:44 EDT

421.44

-5.47

-1.28%

High423.34	Low414.38	Vol2.16M
Open423.30	D1 Closing426.92	Amplitude2.10%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O43.73M	T/O Rate--	Tradable Shares0.00
P/B2.530263	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":421.44095,"timestamp":1779375104044,"preClose":426.91583,"halted":0,"volume":2157058,"delay":0,"changeRate":-0.012824,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-5.474884,"latestTime":"05-21 10:51:44 EDT","open":423.30365,"high":423.34027,"low":414.38052,"amount":43733629.076963,"amplitude":0.020987,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779393600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.530263,"peRate":-8.013549,"turnoverRate":0.005365,"increases":0,"decrements":4,"flats":0,"marketCap":9294981520,"floatMarketCap":8573801472},"requestUrl":"/m/hq/s/BK4556/tweets","defaultTab":"tweets","newsList":[{"id":"2637033880","title":"Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2637033880","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637033880?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:16","pubTimestamp":1779362207,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Beam Therapeutics today and set a price target of $75.00. According to TipRanks, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4556","BK4139","LU1861558580.USD","BK4585","BK4611","LU1861559042.SGD","BK4505","BEAM","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009234","title":"Beam Therapeutics presents Phase 1/2 data for BEAM-302","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009234?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:35","pubTimestamp":1779136507,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency at a sym...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-presents-phase-1-2-data-for-beam-302-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-presents-phase-1-2-data-for-beam-302-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4585","BK4139","BK4588","BK4611","BEAM","BK4505","LU1861558580.USD","LU1861559042.SGD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636006169","title":"Beam Therapeutics presents Phase 1/2 BEAM-302 AATD trial data at ATS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636006169","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636006169?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:00","pubTimestamp":1779134426,"startTime":"0","endTime":"0","summary":"Beam Therapeutics presented additional Phase 1/2 topline clinical data at the ATS 2026 International Conference on BEAM-302, its one-time base-editing therapy for alpha-1 antitrypsin deficiency.The update reinforced early signs that a single dose can correct the underlying genetic cause of disease, with sustained restoration of protein function that could address both lung and liver manifestations.Beam plans to seek accelerated approval, with a pivotal expansion of the ongoing open-label trial expected to add about 50 patients and start in the second half of 2026.Detailed, updated BEAM-302 data are slated for presentation at another medical congress later in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL4GKYL6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","BK4139","BK4556","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","LU2210150020.SGD","BK4505","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BEAM","LU1861558580.USD","BK4611","LU2095319765.USD","LU1861559042.SGD","IE00BN0W2V16.EUR","BK4535","SG9999014005.SGD","BK4588","BK4112","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635254797","title":"Sangamo publishes corporate presentation on neurology genomic medicine platform, Fabry gene therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635254797","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635254797?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:25","pubTimestamp":1778790344,"startTime":"0","endTime":"0","summary":"Sangamo outlined a neurology-focused strategy built around zinc-finger epigenetic regulators paired with its STAC-BBB blood-brain barrier-penetrant AAV capsid platform.Fabry gene therapy ST-920 remains on rolling BLA submission, with nonclinical and clinical modules submitted; completion targeted as early as summer 2026, subject to securing additional funding.Cash and cash equivalents totaled USD 27.6 million as of March 31, 2026; funding runway guided into Q3 2026 under current operating plan, including potential additional cost reductions.Chronic pain program ST-503 is in Phase 1/2 STAND study with six active sites; prion disease program ST-506 remains in CTA-enabling work with GLP toxicology completed and analysis ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL2m9Nh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMO","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635740001","title":"Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635740001","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635740001?lang=en_us&edition=fundamental","pubTime":"2026-05-15 02:57","pubTimestamp":1778785068,"startTime":"0","endTime":"0","summary":"The analysts covering Editas Medicine, Inc. ( NASDAQ:EDIT ) delivered a dose of negativity to shareholders today, by...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/analyst-forecasts-just-became-more-bearish-on-editas-medicin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/analyst-forecasts-just-became-more-bearish-on-editas-medicin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQY","NVIW.SI","QDTE","FTEC","QQQM","TECS","IYW","PSQ","SQQQ","NDX",".IXIC","TQQQ","EDIT","NQmain","QQQA","QQQE","ONEQ","JEPQ","TQQY","BK4556","GPIQ","MNQmain","QQQJ","QQQ","QLD","BK4139","QYLG","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635716508","title":"Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635716508","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635716508?lang=en_us&edition=fundamental","pubTime":"2026-05-14 18:40","pubTimestamp":1778755255,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) said Thursday that preclinical data for its lead therapy, EDIT-401, reduced LDL cholesterol by an average of 90% across all dose groups in on-human primates, supporting its deve","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LDL","EDIT","BK4556","DBB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635771807","title":"Editas Medicine Reports New Preclinical Data Demonstrating Progress of Edit-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2635771807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635771807?lang=en_us&edition=fundamental","pubTime":"2026-05-14 18:01","pubTimestamp":1778752860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA9HNTRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635794420","title":"Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635794420","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635794420?lang=en_us&edition=fundamental","pubTime":"2026-05-14 16:20","pubTimestamp":1778746835,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Crispr Therapeutics AG (CRSP) and Caris Life Science...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-crispr-therapeutics-ag-crsp-caris-life-sciences-inc-cai-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-crispr-therapeutics-ag-crsp-caris-life-sciences-inc-cai-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","BK4588","BK4104","LU1861558580.USD","CAI","BK4137","LU0029874061.USD","LU0128526141.USD","XBI","LABU","BK4112","BLSG","BK4139","BK4210","LU1861559042.SGD","BLSX","CRSP","BK4556","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635732135","title":"Cathie Wood's Flagship Fund Is Largely Missing Out on a Booming Tech-Fueled Bull Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2635732135","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635732135?lang=en_us&edition=fundamental","pubTime":"2026-05-14 12:02","pubTimestamp":1778731352,"startTime":"0","endTime":"0","summary":"The flagship ARK Innovation ETF has seen only tepid gains since the start of the year as the AI trade soars. Cathie Wood's flagship ETF is missing out on big tech-driven gains in 2026.ARK Invest CEO Cathie Wood's flagship exchange-traded fund actively invests in shares of companies expected to be disruptive and innovative. But so far this year, the fund appears to be missing out on big gains tied to technology and artificial intelligence.A tech-driven bull market has sent shares of semiconductor companies and other firms tied to the massive AI buildout - including industrial names like Caterpillar - soaring. The PHLX Semiconductor Index SOX was up around 70% year to date on Wednesday afternoon, as was an ETF that aims to track it SOXQ.The ETF's \"popularity has gone down over the last few years because it has not delivered the level of performance that it did in the past,\" Todd Rosenbluth, head of research at TMX VettaFi, said in a phone interview.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","CCUP","LU2357125470.USD","SG9999014906.USD","LU0738911758.USD","LU1400636491.USD","LU2242649171.HKD","LU1201861165.SGD","LU1032466523.USD","ARKW","LU2552382132.HKD","LU2106854487.HKD","MSFO","IE00BJTD4V19.USD","HK0000306685.HKD","LU1633808545.USD","LU1069347547.HKD","LU2211815571.USD","IE00B4JS1V06.HKD","LU0289960550.SGD","BK4514","LU0879622024.SGD","LU0079474960.USD","MSFW","LU2506952097.USD","LU0354030438.USD","LU2023250843.SGD","IE0004086264.USD","LU1989772923.USD","LU1551013425.SGD","IE0004445239.USD","LU1935042215.USD","IE0034235303.USD","LU1291159041.SGD","BK4608","LU2028103732.USD","LU0070302665.USD","LU1066053197.SGD","IE00B5949003.HKD","CRCG","BK4577","LU1366192091.USD","IE00BZ199S13.USD","LU1153585028.USD","LU1989764664.SGD","LU0964807845.USD","LU0985320562.USD","LU0882574139.USD","LU0742534661.SGD","LU0965509283.SGD","LU0072461881.USD","LU0095938881.EUR","AMDG","AMDS","LU1261432733.SGD","LU0795875169.SGD","LU2048586759.USD","TSLQ","LU1244550494.USD","LU0889566641.SGD","LU0957791311.USD","BK4535","SG9999015341.SGD","LU2272731782.SGD","MSFY","SG9999001424.SGD","LU1582986359.USD","LU1564329115.USD","LU0174119429.USD","BK4611","LU0162691827.USD","GB00B4LPDJ14.GBP","LU2265009873.SGD","LU1221951129.SGD","LU1037948897.HKD","LU1623119135.USD","LU2089283258.USD","LU0320765646.SGD","LU0345770993.USD","LU2237957811.SGD","BK4551","LU0859254822.USD","LU1301847155.USD","LU0661504455.SGD","LU0130517989.USD","LU0106831901.USD","LU0210533765.USD","LU2125154778.USD","LU2471134879.HKD","SG9999002232.USD","TSII","AMDU","BK4561","LU1206712785.SGD","LU1032955483.USD","LU1670756490.USD","NVDG","IE00B3SWFQ91.USD","LU0708995401.HKD","LU0211331839.USD","LU2361044949.HKD","LU0289739343.SGD","TSYY","BK4023","LU0316494557.USD","LU0878866978.SGD","LU1699723380.USD","LU0994945656.USD","LU1951198990.SGD","LU2430703178.SGD","LU0494093205.USD","LU0345769128.USD","LU0820561909.HKD","LU1069344957.HKD","SGXZ81514606.USD","LU0082616367.USD","07766","LU2487616109.SGD","IE00BDRTCR15.USD","DAMD","NVD","LU1551013342.USD","BK4573","LU0276348264.USD","LU0472753341.HKD","IE00B19Z9Z06.USD","LU1235295455.SGD","LU2417539215.USD","AAPW","LU0068578508.USD","LU0648001328.SGD","LU0787776722.HKD","LU2506951875.HKD","LU2954938101.SGD","LU2602419157.SGD","BK4501","LU0557290698.USD","IE00BD6J9T35.USD","TSLW","LU1280957306.USD","LU0672654240.SGD","LU0302445910.USD","ARKK","IE00B4YYXB79.USD","LU2089985449.USD","GB00BDT5M118.USD","LU0444971666.USD","LU0265550359.USD","LU1228905037.USD","LU2362541273.HKD","LU0106261372.USD","LU2999663052.SGD","PRNT","IE00BYQQ9H92.USD","LU2764263039.SGD","LU0894486033.HKD","LU0861579265.USD","LU2355687059.USD","HK0000914660.USD","LU0820561818.USD","LU2148611432.USD","BK4602","CRCD","LU0130102774.USD","LU0208291251.USD","LU0353189763.USD","LU1228905540.USD","LU0784385840.USD","LU2286300806.USD","BK4533","LU1697837992.HKD","LU1852331112.SGD","LU0211326755.USD","LU0545562505.USD","TSLZ","IE00BK4W5L77.USD","LU0345774391.USD","LU0708994859.HKD","LU1043141123.HKD","LU0133085943.USD","LU0158827781.USD","LU1670711123.USD","LU2237957902.USD","SG9999004303.SGD","BK4141","LU0234570918.USD","LU0345770308.USD","LU1116320737.USD","IE00BLSP4452.SGD","LU2357627491.SGD","AAPU","AMDW","LU0096362180.USD","LU2756315318.SGD","BK4555","LU0029864427.USD","LU2125909916.SGD","BK4574","LU1923622291.USD","LU2168563687.JPY","LU2077746001.SGD","NVDB","LU2264538146.SGD","LU2461242641.AUD","LU1674673428.USD","LU0942090050.USD","LU1721428933.USD","LU1202635105.USD","TSLY","SG9999014880.SGD","LU1206713676.USD","TSLT","LU1861559042.SGD","BK4550","LU1989772840.SGD","BK4567","LU1914381329.SGD","LU1868836591.USD","LU0823417653.USD","IE00BVYPNW00.USD","GGLL","AAPY","LU0496365809.HKD","LU0251142724.SGD","LU2247934214.USD","LU1066051225.USD","LU0057025933.USD","LU2357305700.SGD","LU0823434740.USD","ARKG","LU2054465674.USD","SG9999015952.SGD","BK4099","IE0034235188.USD","LU2360107671.USD","LU2089284900.SGD","ANV","BK4613","LU2063271972.USD","LU2100268510.USD","IE00B7KXQ091.USD","LU1804176565.USD","IE00B19Z3B42.SGD","MSFD","LU2360106780.USD","LU1267930227.SGD","LU2430703251.USD","IE00BGHQF631.EUR","LU0143551892.USD","LU1917777945.USD","LU2237443622.USD","IE00BK4W5M84.HKD","IE00B19Z8W00.USD","LU1645745479.HKD","LU0965509101.SGD","LU1712237335.SGD","HK0000819398.USD","LU1974910355.USD","LU2272731865.HKD","LU2404859741.USD","LU1668664300.SGD","LU2097829019.USD","LU2294711713.HKD","LU0274383776.USD","LU2092937148.SGD","BK4612","LU0266013472.USD","LU0640476718.USD","SG9999003800.SGD","AMUU","LU0323239441.USD","LU1691799644.USD","AAPB","LU2168564065.EUR","LU0477156953.USD","LU1496350171.SGD","BK4566","LU0456855351.SGD","LU2543165471.USD","LU2764263203.CNY","LU0256863811.USD","BK4534","LU1861127337.USD","ARKQ","IE00BFSS7M15.SGD","IZRL","LU3102509885.SGD","MSFX","LU0175139822.USD","NVDS","NVDU","IE00BZ9MQY76.HKD","LU1496350502.SGD","AIYY","IE00BVYPNQ40.USD","LU0979878070.USD","LU1043141396.HKD","AMDY","IE00BMPRXQ63.HKD","IE00BJJMRX11.SGD","HK0000320223.HKD","LU0477156797.USD","IE00BFXG0V08.USD","LU2491050071.SGD","LU2236285917.USD","LU1430594728.SGD","LU1181866309.USD","LU2491050154.USD","LU0889565833.HKD","LU1989764748.USD","LU2065170008.USD","LU1196500208.SGD","LU0726765562.USD","LU1861558580.USD","BK4554","BK4528","LU0251132253.USD","HK0000320264.USD","LU0823421416.USD","LU2237443978.SGD","TSLI","LU0690374615.EUR","BK4579","HK0000532082.HKD","LU0466842654.USD","LU1861215975.USD","LU1323610961.USD","LU0960925559.SGD","LU0871640123.AUD","LU1582986433.USD","LU1868836757.USD","IE00BDGV0183.EUR","LU1303367103.USD","LU0187121727.USD","LU0211326839.USD","LU2237438978.USD","IE0003U64NQ7.SGD","HK0000304805.HKD","LU2111349929.HKD","IE00B19Z9505.USD","LU2125909247.SGD","LU2213496289.HKD","LU0077335932.USD","LU1267930490.SGD","LU0312595415.SGD","LU0476273544.USD","LU1935042488.USD","SG9999002224.SGD","LU0642271901.SGD","LU2471134952.CNY","IE000W1ABFV2.USD","LU1861220033.SGD","LU0203347892.USD","IE00BGHQDM52.EUR","LU2041044095.USD","IE000KEQY171.SGD","LU0690374961.EUR","LU1366333091.USD","LU2360108059.USD","IE00BDCRKT87.USD","LU0683600562.USD","IE00BVYPNV92.GBP","LU2592432038.USD","MUU","BK4511","LU1064131342.USD","LU2211814178.USD","BK4525","GGLS","LU1720051017.SGD","LU2491049909.HKD","LU0426417589.USD","LU0130518102.USD","LU2413666426.HKD","LU1035775433.USD","SG9999015978.USD","LU1564329628.SGD","IE000YTNTUN2.SGD","LU2237443465.HKD","LU2210150020.SGD","LU0795875086.SGD","LU2362541513.USD","IE000MB6IJN5.SGD","LU0784383803.USD","LU2095319765.USD","LU0210536198.USD","LU0211328371.USD","BK4605","LU1188199696.SGD","LU2065171311.SGD","LU1003077747.HKD","NVDD","SG9999014567.USD","LU2322448791.USD","BK4077","LU2290526834.HKD","LU0823411888.USD","LU2360032135.SGD","LU0127658192.USD","LU0949170426.SGD","IE0005OL40V9.USD","LU2413666699.HKD","LU1894683264.USD","SG9999015945.SGD","LU0823434583.USD","SG9999014559.SGD","LU2860962120.EUR","LU2381873111.SGD","LU0314106906.USD","LU1074936037.SGD","LU1880398554.USD","LU0107464264.USD","LU0203202063.USD","LU0154236417.USD","LU0094547139.USD","LU1582987597.SGD","IE00BJTD4N35.SGD","LU1489326972.SGD","LU2244417387.USD","IE00BN29S564.USD","LU0353189680.USD","IE00B3M56506.USD","LU2462591350.SGD","IE000F7OJYX1.SGD","LU1803068979.SGD","BK4597","LU2360107168.USD","LU0289961442.SGD","BK4504","IE00BFSS8Q28.SGD","LU0345769631.USD","SGXZ51526630.SGD","LU2420271590.USD","LU2505996681.GBP","IE0009G5SDU7.USD","IE00BWXC8680.SGD","TSLR","LU1861217088.USD","LU1571399168.USD","LU2092627202.USD","IE00BJJMRY28.SGD","BK4604","APLY","IE00BN8TJ469.HKD","TEST","IE00B19Z8X17.USD","LU2191332357.HKD","LU2361044865.SGD","IE0034235295.USD","LU2087625088.SGD","LU1983260115.SGD","LU2168564149.EUR","BK4503","LU0965509010.AUD","LU1582987324.SGD","BK4149","TSLO","LU2083900584.USD","LU2347655156.SGD","LU1861220207.SGD","BK4538","GOU","LU2065169927.USD","LU0069063385.USD","IE00BZ1G4Q59.USD","IE00BQXX3F31.USD","LU2065171402.SGD","LU0215105999.USD","LU2473716301.USD","LU0784385170.HKD","AMYY","IE00BSNM7G36.USD","LU2463028550.USD","SG9999014914.USD","LU2403377893.USD","LU0157215616.USD","LU0965508806.USD","BK4520","LU1236620834.HKD","BK4507","LU1670710588.SGD","LU1435385759.SGD","LU2361045086.USD","LU1066051811.HKD","BK4585","LU2047632596.USD","LU1316542783.SGD","BK4544","LU1923623000.USD","LU2750360997.AUD","LU1242518857.USD","BK4571","LU1839511570.USD","LU0128525929.USD","LU1400636574.HKD","LU1934455277.USD","BK4516","LU0314104364.USD","AVGU","LU1823568750.SGD","LU0689472784.USD","LU0976567544.SGD","LU1244550577.SGD","IE000ITXATA3.USD","LU0308772762.SGD","LU1506573853.SGD","LU2552382215.SGD","LU2322448957.HKD","CRCA","LU2458330243.SGD","SG9999001440.SGD","TSL","LU1988902786.USD","LU1564329461.SGD","SG9999014542.SGD","LU1935043023.USD","NVII","LU2430703095.HKD","TLA","LU2023251221.USD","AAPX","LU1718418525.SGD","SG9999018857.SGD","TEMT","SG9999015358.SGD","LU0097036916.USD","LU1084165304.USD","LU0171293334.USD","LU2125909759.SGD","LU0348723411.USD","AVGG","LU0061474960.USD","LU0347712357.USD","LU0342679015.USD","LU0943347566.SGD","LU0124676726.USD","GB00B4QBRK32.GBP","LU0417517546.SGD","LU2125154935.USD","LU2237443549.SGD","CRSH","LU0985489474.SGD","LU0238689110.USD","BK4512","AMDD","GOOP","LU2471134523.USD","IE00B19Z3581.USD","LU2326559502.SGD","TSLP","LU0158827948.USD","LU0444973449.USD","LU1121112475.USD","LU1814569148.SGD","LU2506951792.HKD","LU1934455194.USD","LU2168564222.USD","LU2023250330.USD","LU2404859667.USD","ARKX","IE00B3S45H60.SGD","IE00B775SV38.USD","LU0868494708.USD","IE000SO60NU8.SGD","IE00BYXW3230.USD","LU0211327993.USD","BK4549","LU0545039389.USD","AMDL","LU0056508442.USD","LU0912757837.SGD","NVDQ","IE00BJLML261.HKD","SG9999000418.SGD","LU0757359954.USD","LU0950375773.USD","LU1791710582.SGD","IE00B775H168.HKD","TSDD","LU1935043536.SGD","BK4587","YMAG","LU0048584097.USD","SG9999014575.USD","ARKF","HK0000914686.HKD","LU0320765489.SGD","LU0310799852.SGD","LU1221951046.USD","LU2433249047.HKD","LU0011850046.USD","LU0823414478.USD","LU2931357623.SGD","SGXZ99366536.SGD","LU2242650005.HKD","LU0784384876.USD","LU1868837136.USD","LU2298321311.HKD","LU2552382058.USD","LU2720916845.USD","LU2249611893.SGD","LU0323591593.USD","LU2237443895.HKD","IE00BBT3K403.USD","IE00BLSP4239.USD","LU0345768153.USD","NVDO","LU1236620750.USD","SG9999017495.SGD","LU0256863902.USD","IE0002270589.USD","LU0957808578.USD","LU2092937221.SGD","LU0265550946.USD","LU0820562030.AUD","LU1429558221.USD","LU1340139317.AUD","BK4515","LU1059921491.USD","IE00B42XCP33.USD","LU0689626769.HKD","IE00B3PB1722.GBP","NVDW","LU2896262040.SGD","BK4592","LU1791710400.SGD","BK4170","LU0390134368.USD","LU0109391861.USD","LU1116320901.HKD","MUD","LU1334329650.SGD","LU2505996509.AUD","SG9999001077.SGD","LU1244550221.USD","LU0267386448.USD","LU0894485498.HKD","LU1989771016.USD","LU1951200564.SGD","LU1992135399.USD","AVGW","LU0433182093.SGD","ICRC","LU0053666078.USD","LU1720051108.HKD","LU2637965513.SGD","LU2458330169.SGD","LU0128525689.USD","LU1267930573.SGD","LU2456880835.USD","LU1119994496.HKD","HK0000304797.USD","LU1267930813.SGD","IE00BMCWC346.EUR","IE0000B7K699.USD","BULZ","BK4505","LU1923622614.USD","LU1670711040.USD","LU1629891620.HKD","BK4559","BK4575","LU0724617625.USD","BK4529","BK4139","LU1066051498.USD","LU2168564495.EUR","LU2237443382.USD","LU1989763005.USD","LU1670627923.USD","LU2271345857.HKD","LU0251131958.USD","LU0949170772.SGD","SG9999018865.SGD","LU0788109477.HKD","BK4548","LU1934455863.HKD","LU2275660780.HKD","IE00BMPRXR70.SGD","LU0061474705.USD","NVDY","LU0109392836.USD","IE00B7SZLL34.SGD","LU0149725797.USD","IE00B894F039.SGD","LU1989773731.SGD","GOOY","LU1894683348.USD","BK4553","IE00B5TLWC47.USD","LU2750360641.GBP","CRCO","BK4614","IE0004091025.USD","GOOW","IE0009356076.USD","LU1235294995.USD","LU0048573561.USD","LU2362540622.SGD","IE000BZT7R73.USD","LU0757359368.USD","LU1162221912.USD","AVS","LU0792757196.USD","AAPD","LU0198837287.USD","IE00BKPKM429.USD","LU0354030511.USD","LU1267930730.SGD","SGXZ31699556.SGD","LU0081259029.USD","LU2023250504.SGD","TSLG","LU2452424414.USD","LU1815336760.USD","BK4581","LU1868837300.USD","IE00B1BXHZ80.USD","LU1145028129.USD","IE0001KFT4U8.USD","IE00BKDWB100.SGD","LU0096364046.USD","LU0528227936.USD","LU0170899867.USD","SG9999011175.SGD","IE00BFMHRM44.USD","LU0823421333.USD","BK4097","LU2125909593.SGD","LU0070217475.USD","LU0345774631.USD","LU0138981039.USD","LU2746668974.SGD","LU1732800096.USD","CTRU","GOOX","DIPS","IE00BKVL7J92.USD","LU1732799900.SGD","IE00BHPRN162.USD","LU2506951958.HKD","LU0426412945.USD","TSLL","LU1400636657.SGD","IE000M9KFDE8.USD","AVGX","LU1815333072.USD","LU2462591277.SGD","LU0072462426.USD","LU0980610538.SGD","MULL","LU2506952170.USD","LU0323240290.USD","LU2250418816.HKD","LU2471134796.USD","NVDL","BK4576","LU1127390331.HKD","LU0823414551.USD","IE000WAW04H5.SGD","IE0004445015.USD","LU0310800965.SGD","IE00BVYPNP33.GBP","LU1232071149.USD","LU0289941410.SGD","LU2098885051.SGD","MSFU","LU0310800379.SGD","LU0052756011.USD","LU0786609619.USD","LU0210528500.USD","LU1778281490.HKD","LU0648000940.SGD","LU1992135472.HKD","LU0225283273.USD","IE00BQXX3C00.GBP","NVDX","LU2097344431.USD","BK4556","LU2279689827.SGD","LU0868494617.USD","LU1035773651.USD","LU2210149790.SGD","LU1037948541.HKD","BK4598","LU1242518931.SGD","TSLS","LU1821325948.USD","IE00B1XK9C88.USD","LU0719512351.SGD","AVL","LU1803068623.USD","LU2087621335.USD","SG9999014898.SGD","LU1880398471.USD","LU0203345920.USD","BK4527","BK4532","LU1670710661.SGD","TESL","MSFL","IE00B19Z9P08.USD","LU2133065610.SGD","LU1201861249.SGD","LU1642822529.SGD","LU2097344357.USD","LU0006306889.USD","LU2746668461.USD","LU0511384066.AUD","LU2462157665.USD","IE00BYV24P56.USD","LU1585245621.USD","LU0080751232.USD","IE00BQXX3D17.EUR","BK4588","BK4543","LU1548497426.USD","LU1868836914.USD","LU1935042991.SGD","LU1670628061.USD","LU0345768740.USD","BK4121","LU0553294199.USD","SG9999015986.USD","LU0130103400.USD","LU2108987350.USD","LU1564329032.USD","LU1674673691.USD","LU0234572021.USD","LU1791807156.HKD","LU2272731600.USD","LU0203201768.USD","IE00BMPRXN33.USD","LU2764262908.HKD","LU0061475181.USD","SGXZ23171101.USD","LU2756315664.SGD","LU0823417737.USD","LU2347655073.USD","LU0320765059.SGD","LU1046421795.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635737678","title":"Intellia Therapeutics Is Maintained at Market Perform by Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2635737678","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635737678?lang=en_us&edition=fundamental","pubTime":"2026-05-14 02:49","pubTimestamp":1778698140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NTLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 14:49 ET (18:49 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","LU1861558580.USD","BK4588","NTLA","BK4556","BK4535","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635279789","title":"High Growth Tech Stocks In The US For May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635279789","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635279789?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:08","pubTimestamp":1778670486,"startTime":"0","endTime":"0","summary":"The United States market has experienced a 1.5% increase over the last week and a substantial 26% rise over the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to capitalize on these favorable conditions.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/high-growth-tech-stocks-in-the-us-for-may-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/high-growth-tech-stocks-in-the-us-for-may-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2063271972.USD","LU1852331112.SGD","LU2360106780.USD","BK4588","BK4157","IE00B19Z9Z06.USD","LPTH","LU2360107168.USD","LU1861558580.USD","LU2250418816.HKD","BK4608","IE00BZ9MQY76.HKD","NTLA","IE00B894F039.SGD","LU0353189763.USD","BK4539","LU1861559042.SGD","BK4613","BK4139","BK4585","BK4556","LU0056508442.USD","LU1861215975.USD","LU0353189680.USD","IE00B19Z9P08.USD","LU2087625088.SGD","BK4023","LU0097036916.USD","BK4535","APPX","APP","LU2290526834.HKD","LU1861220033.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635889147","title":"Intellia Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $25 From $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2635889147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635889147?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:14","pubTimestamp":1778667242,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nAZN4SVZM5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4588","NTLA","BK4585","BK4535","LU1861558580.USD","BK4556","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635207060","title":"Analysts Conflicted on These Healthcare Names: Omnicell (OMCL), Beam Therapeutics (BEAM) and Zentalis Pharmaceuticals (ZNTL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635207060","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635207060?lang=en_us&edition=fundamental","pubTime":"2026-05-13 17:41","pubTimestamp":1778665263,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Omnicell (OMCL), Beam Therapeutics (BEAM) and Zent...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-omnicell-omcl-beam-therapeutics-beam-and-zentalis-pharmaceuticals-zntl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-omnicell-omcl-beam-therapeutics-beam-and-zentalis-pharmaceuticals-zntl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4556","BK4137","BK4581","BK4082","HCSG","BK4505","ZNTL","LABU","XLV","BK4167","BEAM","XBI","LU0128526141.USD","LU1861558580.USD","BK4611","LU1861559042.SGD","BK4535","OMCL","BK4588","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635205666","title":"Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635205666","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635205666?lang=en_us&edition=fundamental","pubTime":"2026-05-13 14:36","pubTimestamp":1778654197,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) opened Q1 2026 with revenue of US$15.0 million and a basic EPS loss of US$0.81, alongside a trailing twelve month net loss of US$394.6 million on revenue of US$66.1 million. Over recent quarters the company has reported revenue ranging between US$12.9 million and US$23.0 million, while basic EPS losses have ranged from US$0.81 to US$1.27. This context may lead investors to focus on how future growth expectations could influence margins from these loss-making...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-quarterly-loss-near-us96-million","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-quarterly-loss-near-us96-million","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4139","LU1861558580.USD","BK4588","BLSG","BLSX","NTLA","BK4556","BK4535","BK4112","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634212404","title":"Beam Therapeutics to present updated BEACON trial biomarker data for risto-cel in SCD at EHA2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634212404","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634212404?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:30","pubTimestamp":1778592657,"startTime":"0","endTime":"0","summary":"Beam Therapeutics set updated biomarker data from Phase 1/2 BEACON trial of investigational autologous cell therapy risto-cel in sickle cell disease for presentation at European Hematology Association 2026 Congress on June 11-14, 2026.New analyses are slated to show risto-cel restored red blood cell health and function, with improvements in sickling behavior and blood flow properties described as comparable to sickle cell trait.Separate model-based meta-analysis is expected to reinforce link between higher fetal hemoglobin levels and better clinical outcomes in sickle cell disease, supporting risto-cel’s proposed mechanism and differentiation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL7XqMGL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4505","IE00BKPKM429.USD","BEAM","LU2210150020.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU1861559042.SGD","SG9999014013.SGD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4611","BK4588","LU0314104364.USD","LU1861558580.USD","SG9999014005.SGD","BK4556","NDAQ","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634974572","title":"Sangamo Therapeutics posts ST-503 nonclinical safety presentation for small fiber neuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2634974572","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634974572?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:18","pubTimestamp":1778581117,"startTime":"0","endTime":"0","summary":"Sangamo published nonclinical safety results for ST-503, an investigational AAV9 gene therapy designed to repress SCN9A  for treatment of small fiber neuropathy.Six-month GLP study in cynomolgus monkeys reported no dose-limiting toxicity following one-time intrathecal dosing at 10,000,000,000,000, 60,000,000,000,000, 90,000,000,000,000 vg/animal.Pharmacology readouts at 6 months showed intended SCN9A repression in dorsal root ganglia, with activity also reported in trigeminal ganglia.Mouse fertility and embryo-fetal development study using a surrogate AAV9 ZFR at 5,710,000,000,000 vg/kg found no test-article-related adverse effects.Integration and germline assessments reported no evidence of AAV germline transmission to offspring, with liver integration profile described as low-level and polyclonal, supporting a low tumor-risk signal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLbbCGnp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMO","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634429743","title":"Sangamo Therapeutics publishes ST-506 nonhuman primate brain presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2634429743","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634429743?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:18","pubTimestamp":1778581084,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics published a research presentation on ST-506, a blood-brain barrier-penetrant AAV gene therapy designed to repress prion protein expression by targeting PRNP in neurons.Nonhuman primate brain data at 28 days post-dose showed 33.9% of superior frontal gyrus neurons classified as ZFR+ versus 0.29% for vehicle.Single-cell analysis showed PRNP expression reduced by more than 95% in ST-506-expressing neurons, with median PRNP spot total intensity down 21.1% in ZFR+ neurons versus vehicle.Program update cited tolerability in nonhuman primates at 1E+14 vg/kg over 28 days, supporting further clinical development in symptomatic prion disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLb5nTGG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","SGMO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634974362","title":"Sangamo publishes TRAC locus modular integrase retargeting presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2634974362","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634974362?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:17","pubTimestamp":1778581073,"startTime":"0","endTime":"0","summary":"Sangamo published a medical research presentation outlining a platform to retarget large serine integrases for targeted gene integration at therapeutically relevant genomic sites.Work described retargeting Bxb1 integrase to TRAC locus, reaching about 29% targeted integration with up to 44% GFP expression in primary human T cells.Zinc finger fusions lifted on-target performance while maintaining a stronger specificity profile than activity-boosting mutations, which reduced specificity in genome-wide off-target assays.Synthetic donor engineering designed to remove need for wild-type Bxb1, with donor changes reported to eliminate top nominated off-target integration sites in K562 cells for most active TRAC reagents.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL4PdtwM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4139","SGMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634425616","title":"A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Progress And New Funding Lift Investor Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2634425616","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634425616?lang=en_us&edition=fundamental","pubTime":"2026-05-12 06:26","pubTimestamp":1778538391,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (CRSP) is back in focus after first quarter 2026 results showed revenue of US$1.46 million and a net loss of US$122.93 million, along with ongoing commentary about CASGEVY commercialization.\nSee our latest analysis for CRISPR Therapeutics.\nThe latest earnings update, CASGEVY launch commentary and the US$600 million convertible notes issue come against a backdrop of a 12.29% 90 day share price return, a 45.86% one year total shareholder return and weaker three and five year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/a-look-at-crispr-therapeutics-crsp-valuation-as-casgevy-prog","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/a-look-at-crispr-therapeutics-crsp-valuation-as-casgevy-prog","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","DCF","LU1861559042.SGD","BK4585","BK4611","LU2065732104.USD","BK4139","PRGS","BK4097","LU1861558580.USD","CRSP","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634236133","title":"Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran","url":"https://stock-news.laohu8.com/highlight/detail?id=2634236133","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634236133?lang=en_us&edition=fundamental","pubTime":"2026-05-12 00:55","pubTimestamp":1778518521,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on NTLA stock, giving a Buy rating today. Myles Minter has given his Buy rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/myles-minter-reiterates-buy-on-intellia-ntla-citing-extended-cash-runway-and-strong-phase-iii-data-for-lonvoguran-ziclumeran-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/myles-minter-reiterates-buy-on-intellia-ntla-citing-extended-cash-runway-and-strong-phase-iii-data-for-lonvoguran-ziclumeran-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4134","BK4585","BK4139","BK4588","III","NTLA","LU1861558580.USD","LU1861559042.SGD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.0459},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.2503},{"period":"ytd","weight":0.087}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4556","nameEN":"BK4556"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gene Editing,BK4556,Gene Editing股票,Gene Editing股票老虎,Gene Editing股票老虎国际,Gene Editing行情,Gene Editing股票行情,Gene Editing股价,Gene Editing股市,Gene Editing股票价格,Gene Editing股票交易,Gene Editing股票购买,Gene Editing股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}